| Administration
& Dosage |
- Genital herpes simplex: initial episode, 400 mg ORALLY 3 times a day or 200 mg ORALLY 5 times a day, for 7 to 10 days
- Genital herpes simplex: episodic therapy, 400 mg ORALLY 3 times a day for 5 days or; 800 mg ORALLY twice a day for 5 days or; 800 mg ORALLY three times a day for 2 days or; 200 mg ORALLY every 4 h, 5 times a day for 5 days; initiate at earliest sign or symptom of recurrence
- Genital herpes simplex: episodic therapy in HIV-infected patient, 400 mg ORALLY 3 times a day for 5 to 10 days
- Genital herpes simplex: suppressive therapy, 400 mg ORALLY twice a day for up to 12 months; alternative dosing, 200 mg ORALLY 3 times a day to 200 mg ORALLY 5 times a day
- Genital herpes simplex: suppressive therapy in HIV-infected patient, 400 to 800 mg ORALLY twice to three times a day
- Genital herpes simplex: severe initial episode, 5 to 10 mg/kg IV every 8 h for 2 to 7 days or until clinical improvement, followed by oral therapy to complete at least 10 days total therapy
- Genital herpes simplex: initial therapy; apply ointment TOPICALLY every 3 h (6 times per day) for 7 days in sufficient quantities to adequately cover lesion
- Herpes labialis, recurrent: initiate treatment early, apply cream 5 times per day for 4 days
- Herpes simplex, mucosal and cutaneous - Patient immunocompromised: 5 mg/kg IV every 8 hr for 7 days
- Herpes simplex, mucosal and cutaneous - Patient immunocompromised: apply ointment TOPICALLY every 3 hours (6 times per day) for 7 days in sufficient quantities to adequately cover lesions
- Herpes simplex encephalitis: 10 mg/kg IV every 8 hr for 10 days
- Herpes zoster, Shingles: 800 mg ORALLY every 4 h 5 times a day for 7 to 10 days
- Herpes zoster, Shingles: immunocompromised patients 10 mg/kg IV every 8 hr for 7 days
- Varicella: 800 mg ORALLY 4 times a day for 5 days
- Congenital herpes simplex: birth to 3 mos of age, 10 mg/kg IV every 8 h for 10 days; doses of 15 to 20 mg/kg IV have been used; CDC recommends 20 mg/kg IV every 8 h, for 21 days for disseminated disease or 14 days for disease of the skin and mucous membranes
- Genital herpes simplex: initial episode, (2 y and older) 200 mg ORALLY 5 times a day, for 10 days
- Genital herpes simplex: episodic therapy, (2 y and older) 200 mg ORALLY every 4 h, 5 times a day for 5 days; initiate at earliest sign or symptom of recurrence
- Genital herpes simplex: suppressive therapy, (2 y and older) 400 mg ORALLY twice a day for up to 12 months; alternative dosing, 200 mg ORALLY 3 times a day to 200 mg ORALLY 5 times a day
- Genital herpes simplex: severe initial episode, (12 y and older) 5 mg/kg IV every 8 h for 2 to 7 days or until clinical improvement, followed by oral therapy to complete at least 10 days total therapy
- Herpes labialis, recurrent: initiate treatment early, apply cream 5 times per day for 4 days
- Herpes simplex, mucosal and cutaneous - Patient immunocompromised: under 12 years of age, 10 mg/kg IV every 8 hr for 7 days; 12 years and older, 5 mg/kg IV every 8 hr for 7 days
- Herpes simplex encephalitis: 3 months to 12 years of age, 20 mg/kg IV every 8 hr for 10 days; 12 years of age and older, 10 mg/kg IV every 8 hr for 10 days
- Herpes zoster, Shingles: (2 y and older) 800 mg ORALLY every 4 h 5 times a day for 7 to 10 days
- Herpes zoster, Shingles: immunocompromised patients (12 y and older), 10 mg/kg IV every 8 hr for 7 days
- Herpes zoster, Shingles: immunocompromised patients (younger than 12 y), 20 mg/kg IV every 8 hr for 7 days
- Varicella: 2 years and older, 20 mg/kg ORALLY 4 times a day for 5 days; children over 40 kg, 800 mg ORALLY 4 times a day for 5 days
|
|
| Adverse
reaction |
- Cardiovascular: Injection site phlebitis
- Dermatologic: Sensation of burning of skin, Topical
- Gastrointestinal: Diarrhea, Nausea, Vomiting
- Neurologic: Central nervous system finding, Agitation, confusion, dizziness, hallucinations, somnolence (less common overall; more common in elderly patients)
- Renal: Serum blood urea nitrogen raised, IV infusion; transient, Serum creatinine raised, IV infusion; transient
- Other: Malais
- Hematologic: Thrombotic thrombocytopenic purpura, Immunocompromised patients; some fatal cases
- Neurologic: Confusion, Confusion, Encephalopathic changes, Lethargy, Encephalopathic changes, Tremor
- Psychiatric: Agitation
- Renal: Hemolytic uremic syndrome, Immunocompromised patients; some fatal cases, Renal impairment
|
|
